Results 31 to 40 of about 22,545,234 (252)
Prognostic factors for survival in patiens with chronic lymphocytic leukemia [PDF]
The purpose of this study is to analyse the quality of the prognostic factors to prognose the survival time and progression for patients with chronic lymphocytic leukemia (CLL) in early stage.
Wijaya, Ferry
core +1 more source
Phosphatidylinositol-3-kinase pathway is constitutively activated in chronic lymphocytic leukemia mainly due to microenvironment signals, including stromal cell interaction and CXCR4 and B-cell receptor activation.
Laia Rosich +10 more
doaj +1 more source
Immune Trait Polygenic Scores Among Survivors of Hodgkin Lymphoma
ABSTRACT Epidemiologic evidence links immune‐related conditions to Hodgkin lymphoma (HL), but the shared genetic architecture remains unclear. Using data from the St. Jude Survivorship Portal, pre‐computed polygenic risk scores (PRSs) for 12 allergy and immune‐related traits were compared between 794 survivors of HL and 3664 survivors of non ...
Ji Yun Tark +3 more
wiley +1 more source
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. [PDF]
Ligation of the cell-surface Fas molecule by its ligand (Fas-L) or agonistic anti-Fas monoclonal antibodies results in the cleavage and activation of the cysteine protease procaspase 8 followed by the activation of procaspase 3 and by apoptosis.
Jones, DT +8 more
core
Background In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited.
Viola Biberacher +10 more
doaj +1 more source
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna +8 more
wiley +1 more source
JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis [PDF]
Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare ...
Ristić Slobodan +5 more
doaj +1 more source
Using peripheral blood for determining B‐cell or T‐cell clonality is more reliable when we use cell‐free RNA (cfRNA) because cells release blood significantly more RNA than DNA. Next‐generation sequencing (NGS) of cfRNA allows us to evaluate fragment cfRNA and evaluate clonality reliably without the need for prior determination of the specific dominant
Adam Albitar +11 more
wiley +1 more source
Introduction Treatment of chronic lymphocytic leukemia of the B-cell-lineage is strongly based upon clinical staging because of the heterogeneous clinical course of this disease.
Sturm Isrid +4 more
doaj +1 more source

